Of these TNF ligands, TRAIL is an attractive therapeutic candidate because it activates the extrinsic death pathway in cancer cells with little cytotoxicity in normal cells [5], and induces apoptosis regardless of the status of the p53 tumor suppressor [6]. This evidence concerns the gene TNFSF10 and cancer.